In vivo acquired resistance to tamoxifen is associated with irreversible loss of IGF1R, upregulation of insulin receptor and enhanced sensitivity to insulin
Hoff, K.;Periakaruppan, P.;Irizarry, V.;Baar, C.;Sachdev, D.
Show abstract
Selective estrogen receptor modulators (SERMs) like tamoxifen are used to treat hormone receptor positive (HR+) breast cancers. Several models of in vitro acquired resistance to tamoxifen using HR+ breast cancer cell lines have been developed. There are few models of resistance to tamoxifen that are generated in vivo. Here, we generated a model of in vivo resistance to tamoxifen. We show that in vivo tamoxifen resistance is associated with loss of IGF1R. This loss is irreversible as it persists even when tamoxifen is removed. In vivo tamoxifen resistance is also associated with upregulation of insulin receptor, specifically the A isoform of IR (IR-A). These resistant cells show enhanced insulin sensitivity compared to the parental endocrine sensitive or in vitro acquired tamoxifen resistant cells. Finally, we demonstrate that in vivo resistance to tamoxifen results in enhanced proliferation in response to insulin. These studies establish that some mechanisms of in vivo resistance to tamoxifen differ from those observed for in vitro acquired resistance and increased dependence on insulin signaling drives endocrine resistance in HR+ breast cancer. Taken together, these studies present that targeting IR-A in combination with newer targets of tamoxifen resistance could be tested in endocrine resistant breast cancer.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity 92%
- Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor 92%
- Identification of Hsp90 inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer 92%
Similar papers in this journal
- The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer 95%
- Epigenetic Modulation of SPCA2 Reverses Epithelial to Mesenchymal Transition in Breast Cancer Cells 93%
- The differential metabolic signature of breast cancer cellular response to olaparib treatment 92%
Similar papers in this journal
- Characterization of a novel estrogen- and progesterone-responsive endometrial cancer cell line: HCI-EC-23 92%
- Low E2F2 activity is associated with high genomic instability and PARPi resistance 92%
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 92%
Similar papers in this journal
- Insulin-Like Growth Factor 1 Receptor Regulates Breast Cancer Cell Adhesion through Beta-1 Integrin 92%
- Proteolytic cleavage of the extracellular domain affects signaling of parathyroid hormone receptor 1 90%
- Effects of systemic oxytocin and beta-3 receptor agonist (CL 316243) treatment on body weight and adiposity in male diet-induced obese rats 90%
Similar papers in this journal
- Pro-apoptotic and anti-invasive properties underscore the tumor suppressing impact of myoglobin on subset of human breast cancer cells 93%
- Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer 92%
- H19 is a PERK-regulated long non-coding RNA that fine-tunes UPR signalling and inhibits endoplasmic reticulum stress-induced cell death 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.